People: Edwards Lifesciences Corp (EW)
EW on New York Consolidated
65.79USD
23 May 2013
65.79USD
23 May 2013
Price Change (% chg)
$1.49 (+2.32%)
$1.49 (+2.32%)
Prev Close
$64.30
$64.30
Open
$63.97
$63.97
Day's High
$66.30
$66.30
Day's Low
$63.95
$63.95
Volume
1,119,366
1,119,366
Avg. Vol
1,430,422
1,430,422
52-wk High
$110.79
$110.79
52-wk Low
$62.34
$62.34
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Michael Mussallem |
60 | 2000 | Chairman of the Board, Chief Executive Officer |
Thomas Abate |
59 | 2010 | Chief Financial Officer, Corporate Vice President |
Aimee Weisner |
44 | 2011 | Corporate Vice President, General Counsel |
Christine McCauley |
48 | 2012 | Corporate Vice President - Human Resources |
Donald Bobo |
51 | 2007 | Corporate Vice President - Heart Valve Therapy |
Bruce Garren |
66 | 2011 | Corporate Vice President - Public Affairs and Special Counsel |
John Kehl |
59 | 2000 | Corporate Vice President - Strategy and Corporate Development |
Paul Redmond |
49 | 2009 | Corporate Vice President - Global Corporate Operations |
Carlyn Solomon |
50 | 2008 | Corporate Vice President - Critical Care and Vascular |
Patrick Verguet |
55 | 2004 | Corporate Vice President, Europe, Middle East and Africa |
Huimin Wang |
56 | 2010 | Corporate Vice President, Japan, Asia Pacific |
Larry Wood |
47 | 2007 | Corporate Vice President - Transcatheter Valve Replacement |
Mike Bowlin |
70 | 2012 | Independent Director |
John Cardis |
71 | 2004 | Independent Director |
Robert Ingram |
70 | 2003 | Independent Director |
William Link |
66 | 2009 | Independent Director |
Barbara McNeil |
72 | 2006 | Independent Director |
David Pyott |
59 | 2000 | Independent Director |
Wesley von Schack |
68 | 2012 | Presiding Independent Director |
David Erickson |
Vice President - Investor Relations |
Biographies
| Name | Description |
|---|---|
Michael Mussallem |
Mr. Michael A. Mussallem is Chairman of the Board, Chief Executive Officer of Edwards Lifesciences Corp. Prior to 2000, he held a variety of positions with increasing responsibility in engineering, product development, and senior management at Baxter International Inc. ("Baxter"), including Group Vice President of its CardioVascular Group from 1994 to 2000, and Group Vice President of its Biopharmaceutical business from 1998 to 2000. Mr. Mussallem received his Bachelor of Science degree in Chemical Engineering from the Rose-Hulman Institute of Technology and was conferred an honorary Doctorate by his alma mater in 1999. He was a director of Advanced Medical Optics, Inc. from 2002 to 2009, where he chaired the Organization, Compensation and Corporate Governance Committee. Mr. Mussallem currently serves on the boards and executive committees of Advanced Medical Technology Association ("AdvaMed"), California Healthcare Institute, and OCTANe Foundation for Innovation, and is a trustee of the University of California, Irvine Foundation. |
Thomas Abate |
Mr. Thomas M. Abate is Chief Financial Officer, Corporate Vice President of Edwards Lifesciences Corp. From 2000 to 2006, he held positions of increasing responsibility, including Controller, Corporate Vice President, Financial Control and Operations, and was Treasurer from 2006 through 2010. Mr. Abate earned a Bachelor's degree in Accounting from the University of Illinois and an MBA from Northern Illinois University. |
Aimee Weisner |
Ms. Aimee S. Weisner is Corporate Vice President, General Counsel of Edwards Lifesciences Corp. From 2009 to 2010, she was engaged in private practice and served as legal advisor to publicly traded pharmaceutical and medical device companies located in Southern California. Prior to this, from 2002 to 2009, Ms. Weisner served in a number of positions at Advanced Medical Optics, Inc., including Corporate Vice President, General Counsel and Secretary; Executive Vice President, Administration, General Counsel and Secretary; and Executive Vice President, Administration and Secretary. From 1998 to 2002, Ms. Weisner served as Corporate Counsel and Assistant Secretary; and then Vice President, Assistant General Counsel and Assistant Secretary at Allergan, Inc. She received her Bachelor's degree in Communications from California State University, Fullerton, her law degree from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O'Melveny & Myers LLP. |
Christine McCauley |
Ms. Christine Z. McCauley is Corporate Vice President - Human Resources of Edwards Lifesciences Corp. Prior to assuming her current role, she served as the Company's Vice President, Human Resources since 1999. Prior to joining the Company, she held a variety of human resources positions at Texas Instruments, Loral (Ford) Aerospace, and Bally's Health and Tennis. Ms. McCauley is a member of the advisory board of Healthcare Businesswomen's Association Southern California Chapter. She earned a dual Bachelor's Degree in Business Administration and Organizational Effectiveness at The College at Brockport State University of New York, and received her Master's Degree in Human Resource Management from Chapman University. |
Donald Bobo |
Mr. Donald E. Bobo, Jr., is Corporate Vice President - Heart Valve Therapy of Edwards Lifesciences Corp. He has also served as Vice President and General Manager of Transcatheter Mitral Repair and as Vice President, Corporate Strategy. Prior to joining the Company in 1995, Mr. Bobo served as Director/General Manager of the Non-Invasive Monitoring Business Unit of InnerSpace, Inc., a medical device startup company. He currently serves as a member of the Board of InnerSpace, Inc. and as a board observer of CardioKinetix, Inc., a healthcare equipment and supply company. Mr. Bobo holds a Bachelor's degree in Mathematics and a Master's degree in Engineering from the University of Southern California. |
Bruce Garren |
Mr. Bruce P. Garren is Corporate Vice President - Public Affairs and Special Counsel of Edwards Lifesciences Corp. He previously served as Corporate Vice President, General Counsel beginning in 2000, and was Secretary from 2000 to 2004. Prior to joining the Company, Mr. Garren was Senior Vice President, General Counsel of Safeskin Corporation. He received his undergraduate degree from Antioch College, his law degree from Cornell Law School, and began his legal career as an associate at Arnold & Porter. He currently serves on the Board of the Alliance for Aging Research in Washington D.C. |
John Kehl |
Mr. John H. Kehl, Jr., is Corporate Vice President - Strategy and Corporate Development of Edwards Lifesciences Corp. Prior to 2000, he served in positions of increasing responsibility at Baxter. Mr. Kehl earned his Bachelor of Arts degree in Business and Economics from Loras College and received his MBA from Loyola University in Chicago. |
Paul Redmond |
Mr. Paul C. Redmond is Corporate Vice President - Global Corporate Operations of Edwards Lifesciences Corp. Prior to this, he was Corporate Vice President and General Manager of the Company's Cardiac Surgery Systems and Vascular businesses. Prior to joining the company in 2007, Mr. Redmond served as Vice President, CardioVascular Technologies and Vice President, New Product Development, at Cordis Cardiology, a Johnson & Johnson company. Mr. Redmond received his Bachelor's degrees in Mathematics and Mechanical Engineering from Trinity College in Dublin, Ireland, and also completed the IEP program at I.N.S.E.A.D., in Paris and Singapore. |
Carlyn Solomon |
Mr. Carlyn D. Solomon is Corporate Vice President - Critical Care and Vascular of Edwards Lifesciences Corp. Prior to joining the Company in June 2005, he served in a number of positions at Baxter, including interim President of the Company's BioScience Division, Vice President of Global Manufacturing, and Vice President of Global Operations. Mr. Solomon has served as an executive board member for the California Manufacturers and Technology Association and the Plasma Protein Therapeutics Association. He also served on the Board of The Baxter International Foundation. Mr. Solomon earned a Bachelor's degree in Industrial Engineering from Kansas State University. |
Patrick Verguet |
Mr. Patrick B. Verguet is Corporate Vice President, Europe, Middle East and Africa of Edwards Lifesciences Corp. Since 1984, he served the Company (or Baxter) in various positions including Vice President of Sales, Europe; Global Business Director for hemofiltration; Business Unit/Country Manager for the Company's operations in Western Europe; General Manager of the Company's operations in Utah; and Vice President and General Manager of the Company's Cardiac Surgery Systems business. Mr. Verguet holds a degree as Doctor in Pharmacy from the University of Besançon. |
Huimin Wang |
Dr. Huimin Wang M.D., is Corporate Vice President, Japan, Asia Pacific of Edwards Lifesciences Corporation. From 2004 to 2010, he served as Corporate Vice President, Japan and Intercontinental and was Corporate Vice President, Japan from 2000 to 2004. Previously, he was a representative director of Baxter Limited, a Japan corporation. Dr. Wang earned his Doctor of Medicine degree from Kagoshima University in Japan and was a Resident and Staff Physician in anesthesiology at Keio University Hospital in Tokyo. He earned his MBA from the University of Chicago. Dr. Wang is a Visiting Associate Professor in the Department of Anesthesiology at Keio University. |
Larry Wood |
Mr. Larry L. Wood is Corporate Vice President - Transcatheter Valve Replacement of Edwards Lifesciences Corp. From March 2004 to February 2007, he served as Vice President and General Manager, Percutaneous Valve Interventions. From 2001 to 2004, he was the Vice President, Global Franchise Management. Since 1985, Mr. Wood served the Company (or Baxter) in various positions including in manufacturing management and as Senior Director of Regulatory Affairs and Clinical Studies for the Heart Valve Therapy business. Mr. Wood holds a Bachelor's degree in Business and an MBA from Pepperdine University. |
Mike Bowlin |
Mr. Mike R. Bowlin is Independent Director of Edwards Lifesciences Corp. He served as the Presiding Director until May 2011. He served as Chairman of the Board of Atlantic Richfield Company (which merged with BP Amoco in 2000) from 1995 until his retirement in 2000, as its President from 1993 to 1998, and as its Chief Executive Officer from 1994 to 2000. Mr. Bowlin has been a director of FMC Technologies, Inc. since 2001. |
John Cardis |
Mr. John T. Cardis is Independent Director of Edwards Lifesciences Corp. Mr. Cardis, a senior partner of Deloitte & Touche until his retirement in 2004, served at Deloitte & Touche for 41 years in positions of increasing responsibility, including as National Managing Partner Global Strategic Clients, as a member of its executive committee for 18 years, and as a member of its board of directors. He has been a director of Avery Dennison Corporation since 2004. Mr. Cardis remains actively involved as a private investor and has served a number of non-profit and community organizations. |
Robert Ingram |
Mr. Robert A. Ingram is Independent Director of Edwards Lifesciences Corp. He has been a General Partner in the firm Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies, since 2007. Mr. Ingram has served as a strategic advisor to the Chief Executive Officer of GlaxoSmithKline plc, a pharmaceutical research and development company, since January 2010. He previously served as Vice Chairman, Pharmaceuticals, GlaxoSmithKline plc, from 2003 through 2009, and Chief Operating Officer and President of Pharmaceutical Operations, GlaxoSmithKline plc, from January 2001 through January 2003. Mr. Ingram has been on the board of directors of Valeant Pharmaceuticals International since 2003, serving as its Chairman of the Board from 2006 to 2008, when he became its lead director. He was again named Chairman of the Board of Valeant from December 2010 until March 2011, after which he was again appointed Lead Director. Mr. Ingram has also been a director of Cree, Inc., since 2008, serving as its Lead Director since October 2011, and Elan Corporation, since December 2010, serving as its Chairman of the Board since January 2011. Mr. Ingram was a director of Wachovia Corporation until 2008, OSI Pharmaceuticals, Inc., until 2010, Lowe's Companies, Inc., until 2011, Pharmaceutical Product Development Inc., until 2011, and Allergan Inc., until 2012. |
William Link |
Dr. William J. Link, Ph.D., is Independent Director of Edwards Lifesciences Corp. He is Managing Director and co-founder of Versant Ventures, a venture capital firm investing in early stage healthcare companies. Prior to co-founding Versant Ventures in 1999, Dr. Link was a general partner at Brentwood Venture Capital. From 1986 to 1997, he was founder, Chairman and Chief Executive Officer of Chiron Vision, which was later sold to Bausch & Lomb, Inc. He also founded and served as President of American Medical Optics, Inc., which was acquired by Allergan, Inc. Dr. Link served as a director of Advanced Medical Optics, Inc., from 2002 to 2009. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link earned his Bachelor's, Master's, and Doctorate degrees in Mechanical Engineering from Purdue University. |
Barbara McNeil |
Dr. Barbara J. McNeil, M.D., Ph.D., is Independent Director of Edwards Lifesciences Corp. Since 1990, she has served as the Ridley Watts Professor of Health Care Policy at Harvard Medical School. In addition, since 1988, Dr. McNeil has served as the chair of the Department of Health Care Policy at Harvard Medical School. Since 1983, she has been a Professor of Radiology at both Harvard Medical School and Brigham and Women's Hospital. Dr. McNeil served as a director of CV Therapeutics, Inc., from 1994 to 2008. She also served as a director of Flagship Global Health, Inc., from 2005 to 2008. Dr. McNeil is a member of the Institute of Medicine of the National Academy of Sciences (where she was formerly chair of its Board of Healthcare Services) and the American Academy of Arts and Sciences. She is a member and former chair of the Medicare Evidence Development and Advisory Committee and is a member of the Blue Cross Medical Advisory Panel. Dr. McNeil holds an M.D. from Harvard Medical School and a Ph.D. in Biological Chemistry from Harvard University. |
David Pyott |
Mr. David E. I. Pyott is Independent Director of Edwards Lifesciences Corp. He has served as Chairman of the Board of Allergan, Inc., a global specialty pharmaceutical and medical device company, since April 2001, as Allergan's Chief Executive Officer since January 1998, as its President from 1998 through January 2006, and again beginning March 2011. Mr. Pyott has been a director of Avery Dennison Corporation since 1999. He serves as Chairman of the Board of the California Healthcare Institute, is on the board and on the executive committee of the Biotechnology Industry Organization (BIO), is on the Directors' Board of the Paul Merage School of Business at the University of California (Irvine), and is a Vice Chairman of the Board of Trustees of Chapman University. Mr. Pyott holds a Diploma in European and International Law from the Europa Institute at the University of Amsterdam, a Master of Arts from the University of Edinburgh, and an MBA from the London Business School. |
Wesley von Schack |
Dr. Wesley W. von Schack is Presiding Independent Director of Edwards Lifesciences Corp. He served as Chairman, President, and Chief Executive Officer of Energy East Corporation, an energy services company, from 1996 until his retirement in 2009 (Energy East Corporation was acquired by Iberdrola S.A. in 2008). Mr. von Schack has been a director of the Bank of New York Mellon Corporation since 2007 and is its lead director and chairman of its executive committee. He has been a member of the board of directors of AEGIS Insurance Services since 1997, its chairman since 2006, and a non-executive director of AEGIS Managing Agency Limited, which manages Syndicate 1225 at Lloyd's of London. Mr. von Schack has been a director of Teledyne Technologies, Inc., since 2006. He received his Bachelor's degree in Economics from Fordham University, an MBA from St. John's University, and Doctorate from Pace University. |
David Erickson |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Michael Mussallem |
7,387,890 |
Thomas Abate |
2,290,120 |
Aimee Weisner |
-- |
Christine McCauley |
-- |
Donald Bobo |
2,024,820 |
Bruce Garren |
-- |
John Kehl |
-- |
Paul Redmond |
-- |
Carlyn Solomon |
2,236,340 |
Patrick Verguet |
2,483,470 |
Huimin Wang |
-- |
Larry Wood |
1,741,840 |
Mike Bowlin |
-- |
John Cardis |
-- |
Robert Ingram |
-- |
William Link |
-- |
Barbara McNeil |
-- |
David Pyott |
-- |
Wesley von Schack |
-- |
David Erickson |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Michael Mussallem |
1,997,397 | 60,284,450 |
Thomas Abate |
181,200 | 12,754,000 |
Aimee Weisner |
0 | 0 |
Christine McCauley |
0 | 0 |
Donald Bobo |
145,330 | 10,357,000 |
Bruce Garren |
0 | 0 |
John Kehl |
0 | 0 |
Paul Redmond |
0 | 0 |
Carlyn Solomon |
73,300 | 4,066,620 |
Patrick Verguet |
247,607 | 9,149,395 |
Huimin Wang |
0 | 0 |
Larry Wood |
50,800 | 2,151,510 |
Mike Bowlin |
0 | 0 |
John Cardis |
0 | 0 |
Robert Ingram |
0 | 0 |
William Link |
0 | 0 |
Barbara McNeil |
0 | 0 |
David Pyott |
0 | 0 |
Wesley von Schack |
0 | 0 |
David Erickson |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
VON SCHACK WESLEY W |
563 | $0.00 |
INGRAM ROBERT ALEXANDER |
2,811 | $0.00 |
LINK WILLIAM J |
563 | $0.00 |
LINK WILLIAM J |
2,811 | $0.00 |
MCNEIL BARBARA J |
563 | $0.00 |
VON SCHACK WESLEY W |
2,811 | $0.00 |
CARDIS JOHN T |
2,811 | $0.00 |
MUSSALLEM MICHAEL A |
70,283 | $71.14 |
PYOTT DAVID E I |
2,811 | $0.00 |
INGRAM ROBERT ALEXANDER |
563 | $0.00 |
MCNEIL BARBARA J |
2,811 | $0.00 |
BOWLIN MICHAEL R |
2,811 | $0.00 |
REDMOND PAUL C |
5,000 | $67.35 |
ABATE THOMAS M |
1,346 | $67.87 |
GARREN BRUCE P |
3,090 | $67.87 |
MCCAULEY CHRISTINE Z |
91 | $67.87 |
MUSSALLEM MICHAEL A |
29,200 | $64.24 |
MUSSALLEM MICHAEL A |
29,500 | $24.42 |
MUSSALLEM MICHAEL A |
300 | $64.60 |
REDMOND PAUL C |
451 | $63.66 |
ABATE THOMAS M |
15,000 | $63.75 |
BOBO DONALD E JR |
865 | $63.66 |
SOLOMON CARLYN D |
902 | $63.66 |
GARREN BRUCE P |
3,836 | $63.66 |
ABATE THOMAS M |
2,296 | $63.66 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
